Table 2.

IFNγ release of CTLs transduced with siRNA10 and maintained in culture with or without CH-11 antibody


CTLs

HLA*typing

A2-CLG

A2-GLC

B8-RAK

B8-QAK

B35-AVL

B35-HPV

CTL alone

A11DEP
1   A1,24;B8,18   —   —   543 ± 83  1199 ± 25   —   —   0   NT  
1 + CH-11   A1,24;B8,18   —   —   615 ± 64   1022 ± 185   —   —   0   NT  
2   A1,2,;B7,B8   499 ± 54   227 ± 21   NT   NT   —   —   0   0  
2 + CH-11   A1,2,;B7,B8   433 ± 2   296 ± 20   NT   NT   —   —   0   0  
3   A2,3;B35,57   208 ± 22   NT   —   —   310 ± 61   533 ± 87   0   0  
3 + CH-11   A2,3;B35,57   203 ± 34   NT   —   —   245 ± 76   553 ± 26   0   0  
4   A1,2;B7,8   12 ± 4   NT   338 ± 34   576 ± 100   —   —   0   NT  
4 + CH-11
 
A1,2;B7,8
 
32 ± 7
 
NT
 
326 ± 26
 
458 ± 50
 

 

 
0
 
NT
 

CTLs

HLA*typing

A2-CLG

A2-GLC

B8-RAK

B8-QAK

B35-AVL

B35-HPV

CTL alone

A11DEP
1   A1,24;B8,18   —   —   543 ± 83  1199 ± 25   —   —   0   NT  
1 + CH-11   A1,24;B8,18   —   —   615 ± 64   1022 ± 185   —   —   0   NT  
2   A1,2,;B7,B8   499 ± 54   227 ± 21   NT   NT   —   —   0   0  
2 + CH-11   A1,2,;B7,B8   433 ± 2   296 ± 20   NT   NT   —   —   0   0  
3   A2,3;B35,57   208 ± 22   NT   —   —   310 ± 61   533 ± 87   0   0  
3 + CH-11   A2,3;B35,57   203 ± 34   NT   —   —   245 ± 76   553 ± 26   0   0  
4   A1,2;B7,8   12 ± 4   NT   338 ± 34   576 ± 100   —   —   0   NT  
4 + CH-11
 
A1,2;B7,8
 
32 ± 7
 
NT
 
326 ± 26
 
458 ± 50
 

 

 
0
 
NT
 

NT indicates not tested; —, not applicable.

*

The following HLA class I-restricted peptides were used for stimulation in an ELISPOT assay: HLA-A2 LMP2 epitope CLGGLLTML (CLG), HLA-A2 BMLF1 epitope GLCTLVAML (GLC), HLA-B8 BZLF1 epitope RAKFQLL (RAK), HLA-B8 EBNA3A QAKWRLQTL (QAK), HLA-B35 EBNA3B epitope AVLLHEESL (AVL), and HLA-B35 EBNA1 epitope HPVGEADYF (HPV).

The A11-DEP peptide was used as irrelevant peptide.

Number of spot-forming cells/105CTL.

Close Modal

or Create an Account

Close Modal
Close Modal